CEACAM5 and neoplasm: Our study focuses on clinical utility of tumor markers CEA, CA19-9, CA72-4, and CA125 in gastric cancer patients with neoadjuvant chemotherapy, and the aim of the study is to measure whether these tumor markers might be useful in monitoring response and in predicting the prognosis of patients.